List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8228008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutations in Hcfc1 and Ronin result in an inborn error of cobalamin metabolism and ribosomopathy. Nature Communications, 2022, 13, 134.	5.8	16
2	How Do Red Blood Cells Die?. Frontiers in Physiology, 2021, 12, 655393.	1.3	61
3	Does <i>neocytolysis</i> exist after descent from high altitude?. Acta Physiologica, 2021, 233, e13713.	1.8	7
4	Iron Deficiency in Polycythemia Vera Increases HIF Activity and Transcription of Prothrombotic Genes. Blood, 2021, 138, 2549-2549.	0.6	2
5	Extracellular mitochondria released from traumatized brains induced platelet procoagulant activity. Haematologica, 2020, 105, 209-217.	1.7	32
6	Cofilinâ€1–induced actin reorganization in stored platelets. Transfusion, 2020, 60, 806-814.	0.8	5
7	Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency. TH Open, 2020, 04, e33-e35.	0.7	10
8	Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Advances, 2020, 4, 1115-1130.	2.5	49
9	Phlebotomy-Induced Iron Deficiency Increases the Expression of Prothrombotic Genes. Blood, 2020, 136, 11-12.	0.6	6
10	<i>CblX</i> is a New Cobalamin Syndrome Affecting Craniofacial Development. FASEB Journal, 2020, 34, 1-1.	0.2	0
11	Downregulated KLF2 in PV and ET May Induce Prothrombotic Gene Expression. Blood, 2020, 136, 13-14.	0.6	0
12	Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel. PLoS ONE, 2019, 14, e0218934.	1.1	12
13	Lactadherin promotes microvesicle clearance to prevent coagulopathy and improves survival of severe TBI mice. Blood, 2018, 131, 563-572.	0.6	59
14	Wdr-1 is essential for F-actin interaction with focal adhesions in platelets. Blood Coagulation and Fibrinolysis, 2018, 29, 540-545.	0.5	1
15	von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury. Blood, 2018, 132, 1075-1084.	0.6	64
16	Upregulation of Tissue Factor May Contribute to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. Blood, 2018, 132, 2513-2513.	0.6	2
17	Cofilin-1 Activation in Stored Platelets. Blood, 2018, 132, 1256-1256.	0.6	0
18	Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoAâ€ <scn>ROCK</scn> pathway. Cancer Medicine. 2017. 6, 809-818	1.3	38

#	Article	IF	CITATIONS
19	A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets, 2017, 28, 99-102.	1.1	18
20	Gelatinous Marrow Transformation Associated with Imatinib: Case Report and Literature Review. Case Reports in Hematology, 2017, 2017, 1-4.	0.3	3
21	Biomarker-based Assessment of Urinary Tract Infection in Persons with Spinal Cord Injury. Open Forum Infectious Diseases, 2017, 4, S352-S352.	0.4	1
22	Abstract WP66: Unexpected Conformational Change of Platelet Glycoprotein Ib (GPIb) Receptor After rt-PA Treatment of Large Vessel Ischemic Stroke. Stroke, 2017, 48, .	1.0	0
23	Cardiolipin-mediated procoagulant activity of mitochondria contributes to traumatic brain injury–associated coagulopathy in mice. Blood, 2016, 127, 2763-2772.	0.6	80
24	Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clinical, 2016, 6, 76-81.	4.1	26
25	Gouty tophi in the bone marrow. British Journal of Haematology, 2016, 172, 9-9.	1.2	5
26	Oxidative Stress in Blood Cells Associated with Obstructive Sleep Apnea Contributes to Absence of Hypoxia-Induced Polycythemia. Blood, 2016, 128, 2442-2442.	0.6	2
27	Upregulation of Thrombo-Inflammatory Pathways May Contribute to Increased Thrombotic Risk in Polycythemia Vera and Essential Thrombocythemia. Blood, 2016, 128, 3143-3143.	0.6	2
28	Wdr1-Dependent Actin Reorganization in Platelet Activation. PLoS ONE, 2016, 11, e0162897.	1.1	10
29	Dasatinib Inhibits Actin Fiber Reorganization and Promotes Endothelial Cell Permeability through RhoA-Rock Pathway. Blood, 2016, 128, 3103-3103.	0.6	Ο
30	HLA class II meets β2-glycoprotein I. Blood, 2015, 125, 2741-2741.	0.6	0
31	HIF-mediated increased ROS from reduced mitophagy and decreased catalase causes neocytolysis. Journal of Molecular Medicine, 2015, 93, 857-866.	1.7	37
32	Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor. Leukemia Research Reports, 2015, 4, 1-3.	0.2	10
33	Cephalosporin Side Chain Idiosyncrasies: A Case Report of Ceftriaxone-Induced Agranulocytosis and Review of Literature. Open Forum Infectious Diseases, 2015, 2, ofv007.	0.4	19
34	Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury. Blood, 2015, 125, 2151-2159.	0.6	127
35	A recombinant fragment of von Willebrand factor reduces fibrin-rich microthrombi formation in mice with endotoxemia. Thrombosis Research, 2015, 135, 1025-1030.	0.8	15
36	Wdr1-Mediated Actin Reorganization Is Essential for Integrin αIIbβ3 Activation in Platelets. Blood, 2015, 126, 2231-2231.	0.6	0

#	Article	IF	CITATIONS
37	Absence of Polycythemia in Obstructive Sleep Apnea (OSA) Is Caused By Neocytolysis. Blood, 2015, 126, 3348-3348.	0.6	0
38	MFG-E8 in the Blood Cell Homeostasis and Coagulation. , 2014, , 65-84.		0
39	Cofilin-1 – Induced Actin Reorganization and Phosphatidylserine Exposure in Platelets. Blood, 2014, 124, 4153-4153.	0.6	2
40	Inherited Giant Platelet Disorder, Kashmiri Thrombocytopenia, a Common Syndrome Found in Srinagar, India. Blood, 2014, 124, 4211-4211.	0.6	2
41	Brain-Derived Microparticles Induce Systemic Coagulation Associated with Traumatic Brain Injury. Blood, 2014, 124, 1497-1497.	0.6	0
42	Neocytolysis Is Mediated by down Regulation of Catalase By Mir-21 Resulting in defective Clearance of reticulocyte mitochondrial ROS. Blood, 2014, 124, 1336-1336.	0.6	0
43	The activity of the androgen receptor variant ARâ€V7 is regulated by FOXO1 in a PTENâ€Pl3Kâ€AKTâ€dependent way. Prostate, 2013, 73, 267-277.	1.2	48
44	Antiplatelet factor 4/heparin antibodies in patients with gram negative bacteremia. Thrombosis Research, 2013, 132, 217-220.	0.8	20
45	Platelet Transfusion Therapy. Hematology/Oncology Clinics of North America, 2013, 27, 629-643.	0.9	20
46	A Novel Molecular Mechanism In The Interplay Of Platelet GPlb-VWF-Fibrin In Thrombus Formation. Blood, 2013, 122, 1065-1065.	0.6	3
47	Rho Associated Coiled-Coil Kinase-1 Regulates Collagen-Induced Phosphatidylserine Exposure in Platelets. PLoS ONE, 2013, 8, e84649.	1.1	13
48	Characterization Of An Acquired IgG Autoantibody To Bβ and γ Chains Of Fibrinogen Resulting In Delayed Fibrin Polymerization and Severe Bleeding. Blood, 2013, 122, 2362-2362.	0.6	0
49	Rho Associated Coiled-Coil Kinase-1 Regulates Collagen-Induced Phosphatidylserine Exposure In Platelets. Blood, 2013, 122, 3509-3509.	0.6	0
50	Developmental Endothelial Locus-1 (Del-1) Mediates Clearance of Platelet Microparticles by the Endothelium. Circulation, 2012, 125, 1664-1672.	1.6	138
51	Molecular Basis of Neocytolysis Blood, 2012, 120, 2093-2093.	0.6	0
52	Anti-Platelet Factor 4/Heparin Antibodies in Patients with Gram Negative Bacteremia. Blood, 2012, 120, 3391-3391.	0.6	0
53	Erythrocyte membrane sulfatide plays a crucial role in the adhesion of sickle erythrocytes to endothelium. Thrombosis and Haemostasis, 2011, 105, 1046-1052.	1.8	18
54	Neocytolysis Is Associated with Changes in Increase of Mitochondrial Content and Impaired Protection From Reactive Oxygen Species. Blood, 2011, 118, 1029-1029.	0.6	0

#	Article	IF	CITATIONS
55	A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice. Translational Stroke Research, 2010, 1, 170-177.	2.3	8
56	Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2010, 2, 1-75.	0.3	50
57	Platelet senescence and phosphatidylserine exposure. Transfusion, 2010, 50, 2167-2175.	0.8	62
58	Phagocytosis of platelet microvesicles and β2– glycoprotein I. Thrombosis and Haemostasis, 2010, 104, 335-341.	1.8	35
59	Howell-Jolly Body–Like Inclusions in Neutrophils of a Transplant Recipient in Association With Ganciclovir Therapy. Archives of Pathology and Laboratory Medicine, 2010, 134, 809-810.	1.2	10
60	Differential Effect of An Autoantibody to Thrombin on Fibrinogen Cleavage and Protein C Activation Blood, 2010, 116, 3652-3652.	0.6	0
61	Clearance of Platelet Microvesicles by Endothelium. the Role of Developmental Endothelial Locus–1 (Del-1). Blood, 2010, 116, 4303-4303.	0.6	0
62	Lactadherin and clearance of platelet-derived microvesicles. Blood, 2009, 113, 1332-1339.	0.6	175
63	Platelet Senescence and Phosphatidylserine Exposure Blood, 2009, 114, 2117-2117.	0.6	0
64	The Role of β2-Glycoprotein I in the Clearance of Platelet Microvesicles Blood, 2009, 114, 145-145.	0.6	0
65	Essential role for Nix in autophagic maturation of erythroid cells. Nature, 2008, 454, 232-235.	13.7	1,008
66	Role of lactadherin in the clearance of phosphatidylserineâ€expressing red blood cells. Transfusion, 2008, 48, 2370-2376.	0.8	32
67	Glycoprotein IIb/IIIa Antagonists in Acute Ischaemic Stroke. Drugs, 2008, 68, 1019-1028.	4.9	30
68	Effect of an anti-sulfatide single-chain antibody probe on platelet function. Thrombosis and Haemostasis, 2008, 99, 552-557.	1.8	10
69	Lactadherin and Clearance of Platelet-Derived Microvesicles Blood, 2008, 112, 1840-1840.	0.6	1
70	Lactadherin mediates sickle cell adhesion to vascular endothelial cells in flowing blood. Haematologica, 2007, 92, 1266-1267.	1.7	14
71	Inhibition of thrombin activity by prothrombin activation fragment 1.2. Journal of Thrombosis and Thrombolysis, 2007, 24, 157-162.	1.0	11
72	Essential Role of Pro-Apoptotic Mechanisms for Production of Normal Erythrocytes and Prevention of Hemolysis Blood, 2007, 110, 426-426.	0.6	3

#	Article	IF	CITATIONS
73	A Novel Whole Blood Real-Time Microparticles Detection Assay Using Lactadherin-Coupled Dynabeads Blood, 2007, 110, 702-702.	0.6	0
74	Cell Membrane Sulfatide Promotes Sickle Cell Adhesion to Endothelium Blood, 2007, 110, 1722-1722.	0.6	3
75	Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Translational Research, 2006, 148, 19-25.	2.2	83
76	Leukocyte adhesion and thrombosis. Current Opinion in Hematology, 2006, 13, 34-39.	1.2	92
77	Transient Neutrophilic Thrombophagocytosis Associated With Citrobacter freundii Septicemia. Archives of Pathology and Laboratory Medicine, 2006, 130, 1754-1755.	1.2	4
78	A Monoclonal Antibody to Lactadherin Inhibits Sickle Red Blood Cell Adhesion to Vascular Endothelial Cells in a Plasma Milieu Blood, 2006, 108, 1236-1236.	0.6	0
79	Tissue-factor–bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood, 2005, 106, 1604-1611.	0.6	887
80	Myeloma with Russell bodies. American Journal of Hematology, 2005, 78, 79-79.	2.0	5
81	Sulfatides Activate Platelets Through P-Selectin and Enhance Platelet and Platelet–Leukocyte Aggregation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 258-263.	1.1	59
82	Effect of P-Selectin on Phosphatidylserine Exposure and Surface-Dependent Thrombin Generation on Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1065-1070.	1.1	77
83	Antiphospholipid Syndrome With Anti-Prothrombin Autoantibodies in a Patient With an Axial-Flow Left Ventricular Assist Device. Journal of Heart and Lung Transplantation, 2005, 24, 1133-1136.	0.3	10
84	The Role of Lactadherin in the Phagocytosis of Phosphatidylserine-Expressing Sickle Red Blood Cell by Macrophages Blood, 2005, 106, 3773-3773.	0.6	0
85	Lactadherin Enhances the Adhesion of Sickle Cells to Vascular Endothelial Cells Blood, 2005, 106, 2341-2341.	0.6	0
86	The role of lactadherin in the phagocytosis of phosphatidylserine-expressing sickle red blood cells by macrophages. Haematologica, 2005, 90, 1267-8.	1.7	15
87	Characterization of autoantibodies against sulfatide from a V-gene phage-display library derived from patients with systemic lupus erythematosus. Journal of Immunological Methods, 2004, 295, 129-137.	0.6	10
88	Lupus-Derived Antiprothrombin Autoantibodies from a V Gene Phage Display Library Are Specific for the Kringle 2 Domain of Prothrombinâ€. Biochemistry, 2004, 43, 4047-4054.	1.2	9
89	Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. Aids, 2004, 18, 329-331.	1.0	24
90	Extremely High Levels of Microvesicle-Associated Tissue Factor in a Patient with Cancer-Related Thrombosis Blood, 2004, 104, 2605-2605.	0.6	5

#	Article	IF	CITATIONS
91	A Critical Role for Membrane Sulfatide in Platelet Aggregation Blood, 2004, 104, 626-626.	0.6	20
92	Down Regulation of Thrombin Procoagulant Activity by Prothrombin Activation Fragment 1.2 Blood, 2004, 104, 1946-1946.	0.6	0
93	In vitro assays for evaluating platelet function. , 2002, , 459-470.		11
94	New Targets for Antithrombotic Drugs. American Journal of Cardiovascular Drugs, 2002, 2, 227-235.	1.0	13
95	Polymorphisms β2-glycoprotein I: phospholipid binding and multimeric structure. Thrombosis Research, 2002, 108, 175-180.	0.8	16
96	Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas. Blood, 2001, 97, 1549-1554.	0.6	34
97	Cholesterol Sulfate. Circulation, 2001, 103, 2032-2034.	1.6	46
98	Role for Sulfatides in Platelet Aggregation. Circulation, 2001, 104, 2955-2960.	1.6	62
99	Atherosclerosis, Autoimmunity, and Systemic Lupus Erythematosus. Circulation, 2001, 104, 1876-1877.	1.6	18
100	Prothrombin Cleaving Antibody Light Chains. , 2000, 77, 115-129.		8
101	Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of ?2-glycoprotein I. American Journal of Hematology, 2000, 65, 160-165.	2.0	25
102	Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation. Translational Research, 2000, 135, 66-72.	2.4	33
103	A New Role for P-Selectin in Shear-Induced Platelet Aggregation. Circulation, 2000, 102, 2045-2050.	1.6	105
104	P-Selectin Expression on Platelets Determines Size and Stability of Platelet Aggregates. Circulation, 2000, 102, 1931-1936.	1.6	271
105	Case in Point. Hospital Practice (1995), 2000, 35, 22-22.	0.5	1
106	Monoclonal Antibody Light Chain with Prothrombinase Activityâ€. Biochemistry, 2000, 39, 6459-6465.	1.2	102
107	Case in Point. Hospital Practice (1995), 1999, 34, 40-40.	0.5	0
108	β <sub>2</sub> -Glycoprotein I Promotes the Binding of Anionic Phospholipid Vesicles by Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2807-2811.	1.1	25

#	Article	IF	CITATIONS
109	Platelet Microparticles Promote Platelet Interaction With Subendothelial Matrix in a Glycoprotein IIb/IIIa–Dependent Mechanism. Circulation, 1999, 99, 2577-2582.	1.6	144
110	Mechanisms of Antithrombotic Drugs. Advances in Pharmacology, 1999, 46, 297-324.	1.2	12
111	Associations of anti-?2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis and Rheumatism, 1999, 42, 268-274.	6.7	69
112	Polymorphism of ?2-glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome. Arthritis and Rheumatism, 1999, 42, 1189-1193.	6.7	30
113	Light-chain paraproteins with lupus anticoagulant activity. , 1999, 62, 99-102.		36
114	Cardiolipin Binding a Light Chain from Lupus-Prone Miceâ€,‡. Biochemistry, 1998, 37, 1430-1437.	1.2	23
115	LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES. Hematology/Oncology Clinics of North America, 1998, 12, 1167-1192.	0.9	30
116	Characterization of β2-glycoprotein I-dependent and -independent "antiphospholipid―antibodies from lupus-prone NZW/BXSB F1 hybrid male mice. , 1997, 56, 86-92.		5
117	Characterization of β2â€glycoprotein lâ€dependent and â€independent "antiphospholipid―antibodies from lupusâ€prone NZW/BXSB F1 hybrid male mice. American Journal of Hematology, 1997, 56, 86-92.	2.0	1
118	Inhibition of Arterial Thrombosis by Recombinant Annexin V in a Rabbit Carotid Artery Injury Model. Circulation, 1997, 96, 2339-2347.	1.6	70
119	Alternative Adhesion Sites in Human Fibrinogen for Vascular Endothelial Cellsâ€. Biochemistry, 1996, 35, 4169-4175.	1.2	57
120	Gouty Arthritis in a Patient With Ivemark Syndrome. Southern Medical Journal, 1996, 89, 834-835.	0.3	0
121	The Role of Carboxy-Terminal Glycosaminoglycan-binding Domain of Vitronectin in Cytoskeletal Organization and Migration of Endothelial Cells. Cell Adhesion and Communication, 1996, 4, 317-325.	1.7	5
122	A modified Arg-Asp-Val (RDV) peptide derived during the synthesis of Arg-Glu-Asp-Val (REDV), a tetrapeptide derived from an alternatively spliced site in fibronectin, inhibits the binding of fibrinogen, fibronectin, von Willebrand factor and vitronectin to activated platelets. Biochimica Et Biophysica Acta - General Subjects, 1991, 1075, 237-247.	1.1	5
123	Fibrin(ogen) peptide B.beta. 15-42 inhibits platelet aggregation and fibrinogen binding to activated platelets. Biochemistry, 1988, 27, 6121-6126.	1.2	21
124	Monoclonal antibodies for specific cell labeling: Considerations, preparations and preliminary evaluation. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1987, 14, 51-58.	0.3	7
125	A human erythroleukemia cell line synthesizes a functionally active glycoprotein IIb-IIIa complex capable of binding fibrinogen. Biochimica Et Biophysica Acta - General Subjects, 1987, 924, 127-134.	1.1	12
126	Membrane proteins on human megakaryocytes and platelets identified by monoclonal antibodies. American Journal of Hematology, 1983, 14, 255-269.	2.0	36

#	Article	IF	CITATIONS
127	MECHANISM OF ACTION OF THE LUPUS ANTICOAGULANT. Annals of the New York Academy of Sciences, 1981, 370, 359-365.	1.8	28